CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 825 full-time employees. The company went IPO on 2020-08-14. The firm develops transformative medicines based on messenger ribonucleic acid, or mRNA. The firm's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The firm's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).

CureVac BV adalah perusahaan biopharmaceutical tahap klinis yang terlibat dalam pengembangan obat-obatan transformasional berbasis asam ribonukleat pengirim (mRNA). Perusahaan ini berkantor pusat di Tuebingen, Baden-Wuerttemberg dan saat ini mempekerjakan 825 karyawan penuh waktu. Perusahaan ini melakukan penawaran umum perdana (IPO) pada tanggal 14 Agustus 2020. Perusahaan mengembangkan obat-obatan transformasional berdasarkan asam ribonukleat pengirim, atau mRNA. mRNA perusahaan dirancang untuk mencegah infeksi dan mengobati penyakit dengan meniru biologi manusia untuk mensintesis protein yang diinginkan. Platform teknologinya mengoptimalkan konstruksi mRNA yang mengkode protein fungsional yang baik menginduksi respons imun yang diinginkan atau menggantikan protein yang cacat atau hilang dengan menggunakan mesin translasi intrinsik sel. Portofolio produk perusahaan mencakup kandidat klinis dan pra-klinis di berbagai indikasi penyakit dalam vaksin profilaksis, onkologi, dan terapi molekuler. Dalam vaksin profilaksis, perusahaan sedang mengembangkan kerangka mRNA generasi kedua terhadap Virus Corona Penyebab Sindrom Pernapasan Akut Berat 2 (SARS-CoV-2) dan berbagai penyakit menular, termasuk influenza musiman, bekerja sama dengan GSK (Glaxo Smith Kline).

CureVac

NVIDIA

Apple

Google

Microsoft

Amazon

Broadcom

Meta Platforms

Taiwan Semiconductor

Tesla

Berkshire Hathaway

Walmart

Eli Lilly

JPMorgan

Visa

Oracle

Exxon Mobil

MasterCard

Johnson & Johnson

Palantir

SPDR S&P500 ETF

ASML

Netflix

Bank of America

AbbVie

Costco

Alibaba

Home Depot

Procter & Gamble

Cisco

Vanguard Total Stock Market ETF

Chevron

Coca-Cola

General Electric

UnitedHealth Group

Wells Fargo

Caterpillar

Morgan Stanley

AstraZeneca

Micron Technology

Goldman Sachs

American Express

Toyota

Novartis

Salesforce

Merck

T-Mobile

Philip Morris

Raytheon Technologies

Royal Bank of Canada

McDonald's

Abbott

Applied Materials

Novo Nordisk

Shopify

Shell

Intuitive Surgical

Invesco QQQ Trust

Citigroup

Lam Research

PepsiCo

Intel

Uber

Disney

QUALCOMM

Intuit

Linde PLC

Blackstone

AT&T

ServiceNow

Amgen

Verizon

NextEra Energy

Charles Schwab

Sony

Booking Holdings

BlackRock

Accenture

Texas Instruments

Danaher

Arista Networks

Banco Santander

Boeing

S&P Global

Toronto-Dominion Bank

Gilead Sciences

Pfizer

Capital One

Adobe

Unilever

Boston Scientific

TotalEnergies

Union Pacific

Lowe's

Analog Devices

CureVac Stock

About CureVac

Key Statistics